Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial

被引：18
|
作者：
Frenel, J-S. [1 ,2 ]
Kim, J-W. [3 ]
Berton-Rigaud, D. [1 ,2 ]
Asher, R. [4 ]
Vidal, L. [5 ,6 ]
Pautier, P. [7 ,8 ]
Ledermann, J. A. [9 ,10 ]
Penson, R. T. [11 ]
Oza, A. M. [12 ]
Korach, J. [13 ,14 ]
Huzarski, T. [15 ]
Pignata, S. [16 ,17 ]
Colombo, N. [18 ,19 ,20 ]
Park-Simon, T-W. [21 ,22 ]
Tamura, K. [23 ]
Sonke, G. S. [24 ,25 ]
Freimund, A. [26 ]
Lee, C. K. [27 ]
Pujade-Lauraine, E. [28 ]
机构：
[1] GINECO, Ctr Rene Gauducheau, St Herblain, France
[2] Inst Cancerol Ouest, St Herblain, France
[3] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] GEICO, Med Oncol, Barcelona, Spain
[6] H Clin Barcelona, Barcelona, Spain
[7] GINECO, Med Oncol, Villejuif, France
[8] Gustave Roussy Canc Ctr, Villejuif, France
[9] NCRI, Dept Oncol, London, England
[10] UCL, London, England
[11] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[12] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[13] ISGO, Dept Gynecol Oncol, Tel Aviv, Israel
[14] Chaim Sheba Med Ctr, Tel Aviv, Israel
[15] Pomeranian Med Univ, Int Hereditary Canc Ctr, Genet & Pathol, Szczecin, Poland
[16] MITO, Dept Urol & Gynecol, Naples, Italy
[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[18] MaNGO, Gynecol Oncol Dept, Milan, Italy
[19] European Inst Oncol, Milan, Italy
[20] Univ Milano Bicocca, Milan, Italy
[21] AGO, Gynecol Oncol, Hannover, Germany
[22] Hannover Med Sch, Hannover, Germany
[23] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[24] DGOG, Dept Med Oncol, Amsterdam, Netherlands
[25] Netherlands Canc Inst, Amsterdam, Netherlands
[26] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[27] St George Publ Hosp, Canc Care Ctr, Sydney, NSW, Australia
[28] ARCAGY GINECO, Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
813MO
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [41] New perspective on maintenance therapies for platinum-sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
    Vergote, I.
    Bours, V.
    Blaumeiser, B.
    Baurain, J-F.
    FACTS VIEWS AND VISION IN OBGYN, 2016, 8 (03): : 161 - 167
  • [42] BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
    Dann, Rebecca Byler
    DeLoia, Julie A.
    Timms, Kirsten M.
    Zorn, Kristin K.
    Potter, Jennifer
    Flake, Darl D., II
    Lanchbury, Jerry S.
    Krivak, Thomas C.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 677 - 682
  • [43] A randomized phase 2 trial comparing efficacy of the combination of the PAR? inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce
    Barry, William Thomas
    Birrer, Michael J.
    Lee, Jung-min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rimel, B. J.
    Buss, Mary K.
    Nattam, Sreenivasa R.
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Obermayer, Elizabeth
    Whalen, Christin
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
    Liu, Joyce
    Barry, William Thomas
    Birrer, Michael J.
    Lee, Jung-Min
    Buckanovich, Ronald J.
    Fleming, Gini F.
    Rime, Bj
    Buss, Mary K.
    Natiam, Sreenivasa R.
    Hurteau, Jean
    Luo, Weixiu
    Quy, Philippa
    Obermayer, Elizabeth
    Whalen, Christin
    Lee, Hang
    Winer, Eric P.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [45] Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study
    Park, Junsik
    Kim, Se Ik
    Jeong, Soo Young
    Kim, Yup
    Bookman, Michael A.
    Kim, Jae-Weon
    Kim, Byoung-Gie
    Lee, Jung-Yun
    GYNECOLOGIC ONCOLOGY, 2022, 165 (01) : 97 - 104
  • [46] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
    Liu, Jihong
    Yin, Rutie
    Wu, Lingying
    Zhu, Jianqing
    Lou, Ge
    Wu, Xiaohua
    Zhou, Qi
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Wang, Jing
    Chen, Youguo
    Cheng, Ying
    Wang, Yueling
    Lu, Weiguo
    Li, Wei
    Ma, Xin
    Hsu, Kate
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
  • [47] Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
    Friedlander, Michael
    Moore, Kathleen N.
    Colombo, Nicoletta
    Scambia, Giovanni
    Kim, Byoung-Gie
    Oaknin, Ana
    Lisyanskaya, Alla Sergeevna
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Banerjee, Susana N.
    Oza, Amit M.
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William Hampton
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Disilvestro, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III
    Hasenburg, A.
    Harter, P.
    Park-Simon, T-W.
    Gropp-Meier, M.
    Heitz, F.
    Soergel, P.
    Ataseven, B.
    Friedlaender, M.
    Hilpert, F.
    Pujade-Lauraine, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 88 - 89
  • [49] Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
    Mirza, Mansoor Raza
    Lundqvist, Elisabeth Avail
    Birrer, Michael
    Christensen, Rene DePont
    Nyvang, Gitte-Bettina
    Malander, Susanne
    Anttila, Maarit
    Werner, Theresa L.
    Lund, Bente
    Lindahl, Gabriel
    Hietanen, Sakari
    Peen, Ulla
    Dimoula, Maria
    Roed, Henrik
    Knudsen, Anja Or
    Staff, Synnove
    Vistisen, Anders Krog
    Bjorge, Line
    Maenpaa, Johanna U.
    LANCET ONCOLOGY, 2019, 20 (10): : 1409 - 1419
  • [50] Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
    Nie, Jing
    Wu, Huina
    Sun, Lei
    Ding, Yanjiao
    Luan, Yepeng
    Wu, Jiyong
    FRONTIERS IN PHARMACOLOGY, 2023, 13
12345